Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 15.90K -99.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.04M |
| EPS | -0.35 |
| Shares Out | 7.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,004 |
| Average Volume | 13,838 |
| Open | 0.1300 |
| Previous Close | 0.1300 |
| Day's Range | 0.0021 - 0.1300 |
| 52-Week Range | n/a |
| Beta | -151,095.14 |
| RSI | 35.92 |
| Earnings Date | May 14, 2026 |
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,... [Read more]
Financial Performance
Financial StatementsNews
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
Eloxx Pharmaceuticals provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation for ELX-02. ELX-02: Regulatory and Clinical Updates for Alport Syndrome Nonsense Mutation Progr...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Eloxx Pharmaceuticals’ treatment of Alport Syndrome was granted orphan status by the FDA, according to a post to the agency’s website.
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an e...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agr...
Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
06:12 EST Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome
Eloxx Pharmaceuticals price target lowered to $30 from $60 at Oppenheimer
Oppenheimer lowered the firm’s price target on Eloxx Pharmaceuticals to $30 from $60 due to the continuing market compression in biotech stocks, while keeping an Outperform rating on the shares.
Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA
Eloxx Pharmaceuticals reported results from an assessment of patient biopsies by NIPOKA GmbH. They have developed a highly accurate method for the quantification of podocyte foot process morphology. T...
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has ent...
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans
Eloxx Pharmaceuticals provides updates on ELX-02, ZKN-013
Eloxx Pharmaceuticals provided an update on the continued advancement of ELX-02 for the treatment of Alport syndrome with nonsense mutations, including additional positive results from its Phase 2 cli...
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations
Eloxx Pharma (NASDAQ:ELOX) Rises on Promising Phase 2 Data in Alport Syndrome
Shares of biopharmaceutical company Eloxx Pharmaceuticals (NASDAQ:ELOX) are on the rise today after it announced positive results from a Phase 2 study evaluating ELX-02 for the treatment of Alport syn...
Eloxx Pharmaceuticals reports Q2 EPS ($1.96) vs ($4.90) last year
“This is a transformative time at Eloxx. With today’s confirmation of the disease modifying potential of ELX-02 in all three patient biopsies from the Alport syndrome trial, we look forward…
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy...
Eloxx Pharmaceuticals reports drug response in all patients treated with ELX-02
Eloxx Pharmaceuticals reported additional positive results from its proof-of-concept Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport syndrome after eight weeks of treatment. El...
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating th...
Eloxx Pharmaceuticals granted extension by Nasdaq to regain compliance
Eloxx Pharmaceuticals received notice from the Nasdaq Listing Qualifications Panel of The Nasdaq Stock Market that it has determined to extend the exception granted on June 2, 2023 to Eloxx…
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received...
Eloxx Pharmaceuticals price target raised to $55 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on Eloxx Pharmaceuticals to $55 from $50 and keeps an Outperform rating on the shares. Eloxx recently updated ELX-02 Phase 2 data for Alport…
Eloxx Pharmaceuticals announces publication on its TURBO-ZM platform
Eloxx Pharmaceuticals announced that Cancer Research Communications has published “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Sub...
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communi...